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Abstract
Mitochondrial respiratory chain defects involving cytochrome c oxidase (COX) are found in a clinically heterogeneous
group of diseases, yet the molecular basis of these disorders have been determined in only a limited number of cases. Here, we
report the clinical, biochemical and molecular findings in 17 patients who all had isolated COX deficiency and expressed the
defect in cultured skin fibroblasts. Immunoblot analysis of mitochondrial fractions with nine subunit specific monoclonal
antibodies revealed that in most patients, including in a patient with a novel mutation in the SURF1 gene, steady-state levels
of all investigated COX subunits were decreased. Distinct subunit expression patterns were found, however, in different
patients. The severity of the enzymatic defect matched the decrease in immunoreactive material in these patients, suggesting
that the remnant enzyme activity reflects the amount of remaining holo-enzyme. Four patients presented with a clear defect
of COX activity but had near normal levels of COX subunits. An increased affinity for cytochrome c was observed in one of
these patients. Our findings indicate a genetic heterogeneity of COX deficiencies and are suggestive of a prominent
involvement of nuclear genes acting on the assembly and maintenance of cytochrome c oxidase. ß 1999 Elsevier Science
B.V. All rights reserved.
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1. Introduction
Mitochondria play a central role in cellular energy
provision by the process of oxidative phosphoryla-
tion. In this metabolic pathway, synthesis of ATP is
driven by a transmembrane proton gradient across
the mitochondrial inner membrane. The proton gra-
dient is sustained by the respiratory chain which cou-
ples transfer of electrons from NADH and FADH2
to molecular oxygen with proton pumping across the
membrane [1]. Three of the four enzyme complexes
of the electron transfer chain contain subunits en-
coded on mitochondrial DNA (mtDNA) and sub-
units encoded on nuclear DNA [2]. The mitochon-
drial genome is transmitted maternally but diseases
associated with respiratory chain dysfunction may
show any mode of inheritance [3].
Cytochrome c oxidase (COX; EC 1.9.3.1) is a
complex metalloprotein embedded in the mitochon-
drial inner membrane and constitutes the terminal
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component (complex IV) of the respiratory chain.
COX de¢ciency is emerging as one of the most com-
mon defects in mitochondrial diseases. In mammals,
COX is composed of three polypeptides (I, II and
III) encoded by mtDNA and ten polypeptides (IV,
Va, Vb, VIa, VIb, VIc, VIIa, VIIb, VIIc, VIII) en-
coded by nuclear DNA [4]. The mitochondrially en-
coded subunits are homologous to the three polypep-
tides found in bacterial terminal oxidases and form
the catalytic core of the enzyme [5]. The function of
the nuclear encoded subunits remains enigmatic.
Studies in yeast have shown that most nuclear-en-
coded subunits are required for assembly of the
holo-enzyme [6]. Kadenbach was the ¢rst to postu-
late that some of these subunits are involved in allo-
steric modi¢cation of the catalytic activity [7]. Sup-
port for this idea is provided by the presence of
tissue speci¢c isoforms of some of the subunits which
could optimize the enzymatic activity to the metabol-
ic demands of di¡erent tissues. In humans, subunits
VIa and VIIa exist as muscle/heart (VIa-H and VIIa-
H) and ubiquitously expressed (VIa-L and VIIa-L)
isoforms [6,8].
The dual genetic origin and isoform complexity of
the enzyme may explain in part the remarkable clin-
ical and biochemical heterogeneity of COX de¢cien-
cies, with di¡erent tissues being a¡ected and with a
variable onset of symptoms [9]. Partial defects of
COX activity, frequently accompanied with other
respiratory chain abnormalities, are often associated
with speci¢c point mutations in tRNA genes or dele-
tions in a subpopulation of the mtDNA (i.e., the
mutation is heteroplasmic). For instance, patients
with the mitochondrial disorders MELAS (mito-
chondrial myopathy, encephalopathy, lactic acidosis
and stroke-like episodes) and MERRF (myoclonic
epilepsy with ragged-red ¢bers) commonly carry a
heteroplasmic A3243G transition in their mitochon-
drial tRNALeuUUR gene or a heteroplasmic A8344G
transition in their mitochondrial tRNALys gene, re-
spectively, and show a COX de¢ciency combined
with a defect of other respiratory chain enzymes
[10].
COX de¢ciency in childhood shows a wide clinical
spectrum and includes infants su¡ering from Leigh
syndrome, a progressive neurodegenerative disorder
characterized by subacute necrotizing encephalop-
athy. Leigh syndrome can result from several inborn
errors of energy metabolism and the very ¢rst muta-
tion in a nuclear gene encoding a respiratory chain
component, the £avoprotein subunit of the succinate
dehydrogenase, was reported in two siblings with this
syndrome [11]. A maternally inherited form of Leigh
syndrome is associated with a heteroplasmic muta-
tion in the mitochondrially encoded subunit 6 of
F1F0-ATPsynthase. While a low mutant load may
result in neurogenic muscle weakness, ataxia and ret-
initis pigmentosa (NARP), a high mutant load can
produce the clinical phenotype of Leigh syndrome
[12].
Although much progress has been made in identi-
fying mitochondrial genetic defects associated with
COX de¢ciency, deleterious mutations in only one
nuclear gene have been identi¢ed to date [13,14]. Di-
agnosis for COX de¢ciency has traditionally relied
on analysis of the enzyme activity but this gives little
information about the primary genetic basis of any
abnormality or its prognosis. We have utilized a bat-
tery of nine subunit speci¢c monoclonal antibodies
which permit a more detailed analysis of the mutant
enzyme. Immunocytochemical analysis of 17 patients
with isolated COX de¢ciency showed a large varia-
tion in subunit expression patterns and suggest the
involvement of many nuclear genes in COX de¢-
ciency.
2. Materials and methods
2.1. Case histories
The clinical presentations of patients included
in this study are given in Table 1. All patients
were diagnosed as COX-de¢cient before the age of
7 years.
2.2. Preparation of mitochondria-enriched fractions
from skin ¢broblasts
Human skin ¢broblasts were cultured under stand-
ard conditions. However, in order to allow the res-
piratory chain defective cells to synthesize nucleic
acids and grow, culture medium was supplemented
with 400 WM uridine and 5 mM pyruvate [15]. Mi-
tochondrial fractions were obtained from digitonin-
treated cells as described by Bourgeron et al. [16].
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2.3. Biochemical analysis
Respiratory chain enzyme activities were measured
spectrophotometrically as previously described [17]
using freeze^thaw permeabilized ¢broblasts. Enzyme
activities were calculated both as residual absolute
activities and relative to each other, allowing better
recognition of partial enzyme defects [18,19]. Kinetic
parameters of COX reactions were determined by
¢tting the rates obtained at varying concentrations
of reduced cytochrome c to a Michaelis^Menten
equation modi¢ed to provide estimates of the Hill
number as well as Vmax and apparent Km [20]. The
protein concentration of solubilized mitochondrial
fractions was determined with the help of the bicin-
choninic acid kit (Pierce, Rockford, IL).
2.4. DNA analysis
Total DNA was extracted from various tissues
(muscle, liver, skin ¢broblasts, lymphocytes) and am-
pli¢ed by the polymerase chain reaction (PCR) using
primers speci¢c for mitochondrial COX genes as de-
scribed [21]. Investigations aimed at detection of
large scale rearrangements of mtDNA and the
MELAS A3243G, MERRF A8344G and NARP
T8993C mtDNA point mutations were performed
according to standard procedures [22]. Total RNA
extracted from cultured skin ¢broblasts was reverse
transcribed using the GeneAmp RNA PCR kit (Ap-
plied Biosystems). COX VIb cDNA was ampli¢ed
using oligonucleotide A5P 1^21 and A3P 404^384 ac-
cording to the sequence previously published [23].
PCR primers for ampli¢cation of the SURF1 gene
were chosen as follows (position respective to the A
of the start codon ATG): A5P nucleotides 348^27,
A3P 273^253; B5P 1474^1495, B3P 1853^1833; C5P
2494^2515, C3P 2763^2743; D5P 3673^3694, D3P
4063^4043; E5P 4294^4314, E3P 4591^4571. Ampli¢-
cation conditions included 30 cycles of 30 s, 94‡C;
30 s, 55‡C; 30 s, 72‡C.
For sequence analysis, ampli¢cation products
were puri¢ed in 2% low-melting-point agarose gels
and recovered by heating for 5 min at 65‡C. Direct
sequencing was performed using 3.2 pmol of the
ampli¢cation primer, 10 ng of DNA and 8.5 Wl of
sequencing reaction mixture (Prism Ready Reaction
Sequencing kit, Perkin Elmer Cetus) on an
automatic £uorimetric DNA sequencer (Applied Bio-
systems).
2.5. Immunoblot analysis
Proteins (2.5, 5 or 10 Wg) were dissociated for 30
min at 37‡C in the presence of 4% sodium dodecyl
sulfate, 2% 2-mercaptoethanol, and resolved on ei-
ther 12.5% or 15% polyacrylamide, 5.5 M urea
mini-gels. Proteins were subsequently electroblotted
onto Immobilon-P poly(vinylidene di£uoride) mem-
branes (Millipore, Bedford, MA) as described [24].
Blots were developed with monoclonal antibodies
against cytochrome c oxidase subunits [24]. After in-
cubation with goat anti-mouse IgG horseradish per-
oxidase conjugate, immunoreactive material was
visualized by chemiluminescence (Renaissance, Du-
Pont NEN). Exposures of ¢lms to the blots were
chosen such that the signals were always within the
linear range. In order to correct for possible unequal
loading of the samples, the signals of the COX sub-
units were compared to the signals obtained with
monoclonal antibodies against two other proteins:
the mitochondrial inner membrane £avoprotein sub-
unit of succinate dehydrogenase [25] and the mito-
chondrial outer membrane voltage-dependent anion-
selective channel (VDAC; monoclonal 31HL, Cal-
biochem). Previous experiments have shown that
the concentration of these polypeptides is not af-
fected by the absence of the COX complex [25,26].
3. Results
3.1. Biochemical analysis
Respiratory chain enzyme activities were deter-
mined spectrophotometrically in freeze^thaw per-
meabilized, cultured skin ¢broblasts from 17 patients
and compared to control values (Table 2). Eight pa-
tients showed signi¢cantly reduced COX activity. In
the other nine patients, the absolute residual COX
activity was low but within the normal range. The
ratio between COX activity and other respiratory
chain activities was, however, signi¢cantly reduced
in these patients, indicating a partial COX de¢ciency.
All other respiratory chain complex activities, as well
as citrate synthase, fumarase and lactic dehydrogen-
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ase, were normal. In 13 patients, the speci¢c defect of
COX found in ¢broblasts was also observed in other
tissues (circulating lymphocytes, liver and/or skeletal
muscle; Table 1).
3.2. DNA analysis
In order to dissect the molecular basis of the COX
de¢ciencies, all patients were initially screened for
large rearrangements of mtDNA and mtDNA point
mutations commonly associated with MELAS,
MERRF and NARP. As this analysis did not reveal
aberrant mtDNA, the genes of the three mitochon-
drially encoded COX subunits (I, II and III) as well
as the £anking tRNA genes were sequenced for 10 of
the 17 patients (nos. 1, 2, 3, 4, 7, 9, 10, 13, 14, 16).
This analysis did not identify any pathogenic muta-
tions.
Table 1
Clinical presentation of 17 patients with isolated COX de¢ciency
Patient Consang./Multiplex Symptoms/syndromes COX de¢ciency identi¢ed in
1 M IUGR, growth failure, hepatic failure, deafness, cataract, facial
dysmorphism
Muscle
Lymphocytes
Fibroblasts
2 C Myoglobinuria Fibroblasts
3 M Encepalopathy, liver failure, hypertrophic cardiomyopathy, gut
involvement
Fibroblasts
4 C, M Truncal hypotonia, retinitis pigmentosa, tubulopathy, pyramidal
syndrome, growth failure
Muscle
Lymphocytes
Fibroblasts
5 Leigh syndrome, truncal hypotonia, encephalopathy, pyramidal
syndrome
Muscle
Fibroblasts
6 Leigh syndrome, growth failure, facial dystonia Muscle
Fibroblasts
7 Truncal hypotonia, cholestatic hepatic failure, growth failure Liver
Lymphocytes
Fibroblasts
8 Growth failure, mental retardation, villous atrophy, truncal
hypotonia, lactic acidemia
Muscle
Fibroblasts
9 C, M Leukodystrophy, peripheral neuropathy, lactic acidosis Muscle
Fibroblasts
10 Leigh syndrome, cerebellar syndrome, spastic paraplegia,
strabismus, nystagmus
Muscle
Lymphocytes
Fibroblasts
11 C IUGR, growth failure, recurrent vomiting and diarrhea, lactic
acidemia
Muscle
Fibroblasts
12 C, M Cerebellar syndrome, peripheral neuropathy, growth failure,
strabismus, retinitis pigmentosa, muscle atrophy
Fibroblasts
13 Truncal hyptonia, growth failure Muscle
Lymphocytes
Fibroblasts
14 Myoglobinuria Fibroblasts
15 C, M Strabismus, muscle atrophy, lactic acidemia Lymphocytes
Fibroblasts
16 C, M Leukodystrophy, truncal hypotonia, growth failure, retinitis
pigmentosa, tubulopathy
Muscle
Lymphocytes
Fibroblasts
17 M Growth failure, hypertrophic cardiomyopathy, nystagmus,
tubulopathy, hepatomegaly
Muscle
Fibroblasts
C, consanguineous family; M, Multiplex family; IUGR, intrauterine growth retardation.
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The recent reports of mutations in the SURF1
gene associated with COX-de¢cient Leigh syndrome
[13,14] prompted us to screen for SURF1 mutations
in our patients presenting with Leigh syndrome.
While no mutations were found in patients 5 and
10, a homozygous 1-base pair deletion within exon
6 of the SURF1 gene was identi¢ed in patient 6. This
base change causes a frameshift mutation resulting in
a premature stop-codon at amino acid residue 187 of
the polypeptide.
3.3. Immunoblot analysis
In order to ¢nd additional clues to guide our ge-
netic investigations, we performed immunoblot anal-
ysis of mitochondria-enriched fractions from ¢bro-
blasts of patients and controls. Fig. 1 shows the
results for ¢ve of the patients and two controls,
and is representative of the various subunit patterns
observed in the 17 patients. Patient 1 presented with
a profound COX de¢ciency (Table 2) and showed
severely compromised steady-state levels of all
COX subunits except subunits IV and Va. Patients
2, 3 and 5 presented with a less severe COX de¢-
ciency (Table 2) and exhibited a less pronounced
decrease of most COX subunits (Fig. 1). In contrast,
patient 4 presented with a severe COX de¢ciency
(Table 2) but this patient showed near normal levels
of COX subunits on Western blots (Fig. 1). Anti-
bodies to the £avoprotein protein subunit of the suc-
cinate dehydrogenase and to the voltage-dependent
anion channel (VDAC) gave similar signals in con-
trols and patient extracts, con¢rming that protein
loading was equal in all lanes.
Table 3 gives a summary of the immunoblot data
obtained with the cultured skin ¢broblasts of all
17 patients. We did not observe a change in the
electrophoretic mobility of any COX subunit. In
13 out of the 17 cases, the steady-state levels of sev-
eral subunits were found to be decreased with sub-
units II, III and VIa-L generally being the most se-
verely a¡ected and subunits IV, Va and Vb being the
least a¡ected (Table 3). This subunit expression
pattern was observed in particular in ¢broblasts
from patient 6 who was found to carry a mutation
in the SURF1 gene. Comparison of the quantitative
changes in COX subunits and the severity of the
enzymatic de¢ciency in this group of 13 patients
revealed a correlation between these parameters
(Fig. 2).
Despite the COX de¢ciency (Table 2), patients 4,
7, 10 and 14 showed near normal enzyme subunit
steady-state levels (Table 3). These observations sug-
gest that this group of patients harbors a mutation
a¡ecting the catalytic activity of the enzyme that
does not a¡ect enzyme stability or assembly. More
detailed kinetic studies revealed a decreased Km for
cytochrome c (0.38 WM; control n = 5: 3.5 Wm
( þ 1.0)) in patient 4, while the Km in the other three
patients was normal. Subunits II and VIb are puta-
tively involved in cytochrome c binding [4] but no
mutations were found in the COX II gene or in the
COX VIb cDNA of patient 4.
Fig. 1. Immunoblots with mitochondrial proteins isolated from
patient (P) and control (C) skin ¢broblasts. The upper blot was
developed with a monoclonal antibody against VDAC; the sec-
ond blot was developed with monoclonal antibodies against the
£avoprotein (Fp) of succinate dehydrogenase and subunit I of
COX; the lower blots were developed with speci¢c antibodies
against the various COX subunits as indicated.
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4. Discussion
In this report, we present the results of a compre-
hensive biochemical, genetic and immunoblot analy-
sis of cultured ¢broblasts from patients with isolated
COX de¢ciency. In previous studies, analysis was
restricted to one or a few patients and a limited
number of COX subunits [27^32]. We have examined
17 cases and have investigated the steady-state levels
of nine of the 13 COX subunits with subunit speci¢c
monoclonal antibodies.
Heteroplasmic mutations in mitochondrially en-
Table 2
Spectrophotometric analysis of respiratory chain in cultured skin ¢broblasts from patients
Patient Enzyme activity (nmol/min/mg protein) Activity ratios
SQDR QCCR COX SCCR COX/SCCR QCCR/SCCR
1 27 40 4 20 0.2 2.0
2 nd 63 36 25 1.4 2.5
3 21 107 62 41 1.5 2.6
4 nd 80 12 32 0.5 2.5
5 21 105 54 38 1.3 2.8
6 25 86 30 28 0.9 3.1
7 nd 27 61 51 1.2 2.5
8 25 118 21 38 0.5 3.1
9 21 119 25 38 0.6 3.1
10 nd nd 55 28 1.95 ^
11 21 93 52 36 1.4 2.6
12 6 107 54 40 1.3 2.7
13 nd 141 27 60 0.4 2.4
14 30 169 83 52 1.6 3.2
15 26 79 61 38 1.6 2.1
16 nd 115 28 19 1.4 2.8
17 21 84 57 26 2.2 3.2
Controls (n = 56) 12^42 33^187 47^182 16^68 3.0 þ 0.4 2.9 þ 0.3
Enzymes were measured as described in Section 2. SQDR, succinate quinone DCPIP reductase (complex II) ; QCCR, quinol cyto-
chrome c reductase (complex III); COX, cytochrome c oxidase (complex IV); SCCR, succinate cytochrome c reductase (complex
II+III) ; nd, not done. Abnormal results are indicated in bold characters.
Values for controls: range for control values are given for absolute activities ; ratios in controls are given as mean þ 1 S.D.
Table 3
Immunoblot analysis of mitochondrial proteins from skin ¢broblasts from 17 patients and 2 controls
C1 C2 P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12 P13 P14 P15 P16 P17
SDH-Fp ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++
VDAC ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++
COX I ++ ++ 33 +3 + ++ + 3 ++ + 33 + +3 +3 33 ++ +3 +3 ++
COX II ++ ++ 33 + + ++ + 3 ++ 3 33 ++ 3 3 33 ++ +3 +3 +3
COX III ++ ++ 33 3 3 ++ 33 33 ++ 33 333 ++ +3 +3 333 + 3 3 3
COX IV ++ ++ +3 +3 + ++ + +3 ++ +3 33 ++ +3 3 3 ++ +3 +3 ++
COX Va ++ ++ +3 3 + + + + + + +3 ++ + +3 +3 ++ + ++ ++
COX Vb ++ ++ 33 +3 +3 + + ++ ++ ++ 33 ++ +3 +3 33 ++ + + +
COX VIa ++ ++ 333 3 3 ++ 3 333 + 33 333 ++ +3 3 333 + +3 + +3
COX VIb ++ ++ 33 3 3 + 3 3 ++ + 33 ++ + +3 33 + + +3 +
COX VIc ++ ++ 33 3 + ++ +3 33 ++ 3 33 ++ + +3 33 ++ +3 3 +3
Conditions as in Fig. 1. Symbols correspond to percent of densitometric values as compared to controls: ++, s 80% (normal); +,
61^80% (somewhat below normal); +3, 31^60% (below normal); 3, 11^30% (considerably below normal); 33, 1^10% (detectable
only after prolonged exposure); 333, 0% (not detectable).
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coded COX genes have been reported in a small
number of cases with isolated COX de¢ciency [33^
36]. We determined the DNA sequence of the three
mitochondrially encoded COX genes in ten of our
patients but failed to detect any potentially patho-
genic base changes. In a previous study, no mtDNA
mutations were found in 18 cases with isolated COX
de¢ciency, suggesting that mutations in the genes for
subunit I, II and III are not common in patients with
COX de¢ciency [21]. The rarity of mtDNA muta-
tions in these cases is further supported by the re-
ported high rate of parental consanguinity in chil-
dren with cytochrome c oxidase de¢ciency [3].
Seven of our 17 patients came from consanguineous
families (Table 1).
Mutations in the nuclear-encoded COX genes have
not been identi¢ed [32,37] but, recently, mutations in
the SURF1 gene were found to be associated with
COX-de¢cient Leigh syndrome [13,14]. The SURF1
gene was previously shown to be part of a highly
conserved gene cluster [38]. The yeast homologue
encodes a mitochondrial inner membrane protein re-
quired for electron transfer between complexes of the
respiratory chain and COX assembly or stability [39].
Sequencing of the SURF1 gene in our three patients
with Leigh syndrome revealed in one patient of Ital-
ian origin a novel mutation which, like most of the
other reported mutations, is predicted to lead to a
truncated protein product. On the other hand, the
absence of a mutation in the SURF1 gene in two
of our patients con¢rms the heterogeneity of the mo-
lecular basis of COX de¢ciency in Leigh syndrome.
Immunoblot analysis of ¢broblast mitochondria
revealed a partial de¢ciency of COX subunits in 13
of the 17 patients. The de¢ciency a¡ected both mi-
tochondrially and nuclear-encoded subunits (Table
3). COX activity corresponded with the overall sub-
unit steady-state levels in this group of patients (Fig.
2), suggesting that the defect in these patients a¡ects
predominantly the concentration of fully formed en-
zyme complex and not its intrinsic catalytic activity.
Studies in yeast have revealed the existence of an
ATP-dependent proteolytic pathway responsible for
the clearing of unassembled and improperly folded
polypeptides in the various subcompartments of mi-
tochondria [40]. This proteolytic system is responsi-
ble for the rapid degradation of COX subunits in
yeast strains unable to complete assembly of the
holo-enzyme due to lack of one of the subunits or
of assembly-assisting proteins [41,42]. The proteolytic
system appears to be conserved in mammals [43,44].
Low steady-state levels of nuclear-encoded COX
subunits have been found in mouse and human cell
lines that do not express the mtDNA-encoded sub-
Fig. 2. Relationship between the overall COX subunit steady-state levels and the severity of the enzyme defect. Symbols as in Table
3. Intensities of gray correspond to decreasing concentrations of COX subunits. Enzyme de¢ciency is shown as COX/SCCR ratio.
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units [25,45^48], and it has been demonstrated by
pulse^chase labeling experiments that these low
steady-state levels are the result of an increased turn-
over rate [47]. Furthermore, Hayasaka and col-
leagues [28] have shown that the reduced COX con-
tent in ¢broblasts cultures from two patients with
COX-de¢cient Leigh syndrome, was the result of
an elevated rate of degradation. Thus, the decreased
subunit steady-state levels observed in our patients
are most likely the result of proteolytic degradation
of unassembled or misfolded subunits.
In some cases, subunit VIa-L was undetectable
(Table 3) but it is unlikely that a complete lack of
this subunit is the primary cause of the phenotype
observed in these patients because studies in yeast
have demonstrated that this highly conserved poly-
peptide is not necessary for activity or assembly of
the complex [49]. In most patients, the steady-state
levels of subunits IV, Va and Vb were less a¡ected
than the levels of the other subunits. Subunit IV
appears to have an intrinsic stability [46] and is
present at 40% of control values in human cell cul-
tures depleted of mtDNA (rho‡ cells) [26]. Subunits
Va and Vb do not span the inner membrane and are
located on the matrix side of the enzyme complex
where subunit Va interacts with subunit IV [4]. These
subunits may already be folded prior to assembly,
with subunits IV and Va forming a subcomplex,
making them less prone to proteolytic degradation.
Although we have excluded mitochondrial muta-
tions in ten of the 17 patients, missense mutations
resulting in a decreased assembly or stability of the
holo-enzyme could be present in the mtDNA of the
remaining seven patients. Furthermore, the patients
could harbor mutations in nuclear genes involved in
the addition of the heme A or copper prosthetic
groups, or at other stages of the assembly process
unique to COX. Such genes have been shown to be
essential for COX assembly in yeast and mutations
in these genes lead to reduced steady-state levels of
the COX subunits [50^55]. The residual subunit pat-
terns of these mutant yeast strains are di¡erent and
depend on the mutated gene. In our patients, we
observe dissimilar subunit patterns, suggesting di¡er-
ent genetic defects. Indeed, sequencing of the SURF1
gene in patients 5, 6 and 10, which all have COX
de¢ciency and Leigh syndrome but clearly distin-
guishable subunit patterns (Table 3), demonstrated
a mutation in patient 6 but not in patients 5 and
10. The SURF1 gene mutation appears to have a
drastic a¡ect on COX subunit levels (Table 3, patient
6) and the characterized subunit ¢ngerprint may be
useful for diagnostic purposes. Our knowledge of the
assembly pathway of human COX is limited to two
partly characterized assembly intermediates [56] and
we are currently unable to relate the other subunit
patterns to speci¢c molecular genetic defects. De-
tailed studies in yeast and mammalian cells may al-
low us to link the subunit ‘signatures’ to speci¢c
genetic defects in future.
In four of our 17 patients (patients 4, 7, 10 and
14), immunoblot analysis indicated near normal
steady-state levels of all COX subunits despite clearly
reduced COX activity (Tables 2 and 3). Enzyme ki-
netic studies revealed an increased a⁄nity for the
substrate cytochrome c in patient 4. The reduced
COX activity in patient 4 is thus probably related
to a defect in the interaction of the enzyme with
cytochrome c. Abnormal kinetic behavior of COX
has been observed in other patients [30,57,58] but
an increased a⁄nity for cytochrome c has never
been reported. Based on the crystal structure, Tsuki-
hara and colleagues [4] have proposed a cytochrome
c binding site which is comprised of the three mito-
chondrially encoded subunits I, II and III and the
nuclear-encoded subunits VIa and VIb. Sequencing
of the mitochondrial COX genes excluded mutations
in subunits I, II and III. A mutation in subunit VIa-
L is highly unlikely because subunit VIa is expressed
as a di¡erent isoform in skeletal muscle [8], while the
biochemical defect was present in skeletal muscle as
well as lymphocytes and ¢broblasts (Table 1). Se-
quencing of subunit VIb cDNA did not reveal a
mutation and we are currently considering the se-
quencing of other COX subunits with domains lo-
cated in the vicinity of the putative cytochrome c
binding site.
Kinetic analysis of the enzyme in the other three
patients with normal concentrations of COX sub-
units did not reveal an alteration in the apparent
a⁄nity for cytochrome c. The decrease in enzyme
activity is, therefore, probably related to defects in
the electron transfer or proton pumping properties of
the enzyme. The mitochondrially encoded subunits
play a pivotal role in these activities [5,6] but se-
quencing of the mitochondrial genes did not reveal
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any potentially pathogenic mutations. The nuclear-
encoded subunits are thought to play a regulatory
role in the catalytic functions of the enzyme [7] and
we are now contemplating sequencing of cDNAs for
the ten nuclear-encoded subunits.
Recent genetic studies of patients with COX-de¢-
cient Leigh syndrome have shown mutations in the
SURF1 gene for patients falling into one comple-
mentation group [13,14,59]. Our study of 17 patients
with isolated COX de¢ciency suggests a large genetic
heterogeneity. DNA sequencing showed that only
one of our three patients with COX-de¢cient Leigh
syndrome carried a mutation in the SURF1 gene. We
expect that the detailed description of COX subunit
expression patterns will guide our future e¡orts to
determine the genetic lesion in the other patients
with COX de¢ciency.
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